Leqembi approved by the EU for early-stage Alzheimer’s in patients with specific ApoE4 gene profile, marking a milestone in ...

The antiviral drug tecovirimat (Tpoxx) didn't accelerate lesion clearance in adults and children with clade 1 mpox ...

The trial will assess the therapy’s pharmacokinetics, pharmacodynamics and safety, as well as its impact on disease activity.

Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Cullinan Therapeutics (CGEM) announced that the European Medicines Agency, EMA, approved the Company’s Clinical Trial Application, CTA, for ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

Raw material dependency and transport bottlenecks, not just production capacity, are the key challenges facing the EU's radiopharmaceutical sector, according to the European Medicines Agency (EMA). Vi ...

Substandard and fake medicines remain a major threat in Africa, risking lives and fuelling drug resistance. A unified ...

Anavex could secure conditional approval for blarcamesine, though longer trials may be needed. Check out why AVXL stock is a ...